Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
ConclusionDue to unpredictability of this rare immune related adverse event (irAE), diabetes-related autoantibodies and C-peptide are recommended to be tested before immunotherapy, and plasma glucose monitoring should be performed. After plasma glucose is well controlled using insulin therapy, PD-1 inhibitor treatment might be continued, especially when the immunotherapy is effective.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Cancer & Oncology | Carcinoma | China Health | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Hepatocellular Carcinoma | Immunotherapy | Insulin | Liver Cancer | Lymphoma | Oral Cancer